Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02938793 · ClinicalTrials.gov registry record · Phase 2
Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors
A Phase 2 study, sponsored by Prisma Health-Upstate.
- Terminated
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT02938793 is a Phase 2 study that was terminated before completion, run by Prisma Health-Upstate. The registered enrollment target is 92 participants.
The verdict
NCT02938793, a Phase 2 study, was terminated before completion, sponsored by Prisma Health-Upstate.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
This is an investigator initiated single institution, open-label study to evaluate the antitumor activity, safety, and tolerability of durvalumab in combination with tremelimumab in subjects with select advanced rare solid tumors.
Interventions
- DRUG Durvalumab
- DRUG Tremelimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2016-12-01 |
| Est. Completion | 2025-09-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02938793
The ClinicalTrials.gov registry entry for NCT02938793 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prisma Health-Upstate, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Durvalumab is the first listed.
NCT02938793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02938793 about?
NCT02938793 is a clinical study titled "Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors". This is an investigator initiated single institution, open-label study to evaluate the antitumor activity, safety, and tolerability of durvalumab in combination with tremelimumab in subjects with select advanced rare solid tumors.
What is the current status of trial NCT02938793?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2016-12-01. Estimated completion is 2025-09-17.
What interventions are being tested in trial NCT02938793?
The interventions under investigation include: Durvalumab (DRUG), Tremelimumab (DRUG).
Who is sponsoring clinical trial NCT02938793?
This trial is sponsored by Prisma Health-Upstate, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.